Company intelligence / Profile preview

Prolifico Group

São Paulo, São Paulo, Brazil

Ownership: Private
Development stage: Other

Overview

Prolifico Group is a Brazil-focused alternative real estate and private equity investment firm rather than a biotech or pharmaceutical developer. The company acquires, develops, and manages assets for high-yield business models in Brazil, and one of its healthcare-related activities is investment in post-acute care hospital infrastructure. Through this strategy, Prolifico has participated in the development of facilities operated in the post-acute care segment, including the YUNA operating model described on its website. Based on the available evidence, Prolifico is best characterized as a healthcare-adjacent investor and asset developer, not a life sciences R&D company with a therapeutic pipeline.

Therapeutic areas: Other
Industry: Investors

Beyond the preview

Go deeper on Prolifico Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prolifico Group.

Explore the full profile